Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Elsevier and Doctors Without Borders Partner to Help Tackle Africa's Health Challenges


News provided by

Elsevier

Oct 25, 2016, 08:13 ET

Share this article

Share toX

Share this article

Share toX

AMSTERDAM, October 25, 2016 /PRNewswire/ --

The Elsevier Foundation provides a three-year $300,000 grant to MSF/Epicentre's Niger Research Center

Since May 2014, Epicentre has been rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines and less packaging needs. If proven safe and effective, the new vaccine could be a game changer especially for the children in Sub Saharan countries. In the Maradi region, 7700 children have been included in phase III of the clinical trials (PRNewsFoto/Elsevier)
Since May 2014, Epicentre has been rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines and less packaging needs. If proven safe and effective, the new vaccine could be a game changer especially for the children in Sub Saharan countries. In the Maradi region, 7700 children have been included in phase III of the clinical trials (PRNewsFoto/Elsevier)
Since May 2014, Epicentre has been rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines and less packaging needs. If proven safe and effective, the new vaccine could be a game changer especially for the children in Sub Saharan countries. In the Maradi region, 7700 children have been included in phase III of the clinical trials (PRNewsFoto/Elsevier)
Since May 2014, Epicentre has been rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines and less packaging needs. If proven safe and effective, the new vaccine could be a game changer especially for the children in Sub Saharan countries. In the Maradi region, 7700 children have been included in phase III of the clinical trials (PRNewsFoto/Elsevier)
Since May 2014, Epicentre has been rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines and less packaging needs. If proven safe and effective, the new vaccine could be a game changer especially for the children in Sub Saharan countries. In the Maradi region, 7700 children have been included in phase III of the clinical trials (PRNewsFoto/Elsevier) Since May 2014, Epicentre has been rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines and less packaging needs. If proven safe and effective, the new vaccine could be a game changer especially for the children in Sub Saharan countries. In the Maradi region, 7700 children have been included in phase III of the clinical trials (PRNewsFoto/Elsevier)

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and renowned international humanitarian-aid organization Doctors Without Borders/Médecins Sans Frontières (MSF), have agreed to cooperate in fighting the root causes of some of Africa's most vexing health challenges, including diarrhea and infectious diseases, which leave millions of people dying or severely diminished every year.

     (Photo: http://photos.prnewswire.com/prnh/20161025/432178 )
     (Photo: http://photos.prnewswire.com/prnh/20161025/432177 )

As part of the agreement, the Elsevier Foundation has awarded a $300,000 partnership grant to Epicentre's Niger Research Center which was founded in 2009 to produce high-quality and high-impact studies aimed at transforming medical practice. The African-led research center focuses on adapted, concrete responses to diarrheal diseases, malnutrition and malaria. The three-year partnership will support the development of Epicentre's medical and scientific staff training and mentoring and aims to boost the Center's overall visibility through a "Scientific Day" Conference to be held in Niger.

The joint Collaboration Agreement represents a cooperative effort between four organizations: Doctors without Borders, Epicentre (Doctors without Borders' research and training arm), the Elsevier Foundation (Elsevier's corporate charity focused on global health and research capacity building) and Elsevier, which will provide courtesy access to products and services such as ScienceDirect, Scopus, Clinical Key, Embase and Mendeley.

Youngsuk "YS" Chi, President of the Elsevier Foundation, underscored: "Our goal is to support MSF and Epicentre's mission to empower trained local medical staff in Africa to provide high-quality care in their home countries. This work resonates well with the Elsevier Foundation's focus on supporting the United Nations' Sustainable Development Goals through the development of science, technology and medicine in Africa and across the world."

Jérôme Oberreit, Secretary General of MSF, said: "Elsevier's support of our work goes beyond financial support. It will allow our medical teams to have access to scientific, technical and medical information that is essential to improve the quality of humanitarian healthcare MSF provides to the most vulnerable populations in the world."

Ron Mobed, CEO of Elsevier, said: "Both Elsevier and MSF share a commitment to advancing healthcare and research in developing and emerging markets. We hope that providing MSF and Epicentre with essential clinical tools such as ClinicalKey and ScienceDirect will equip them with the timely, accurate knowledge they need to develop treatment protocols for doctors, nurses and epidemiologists tackling epidemics, malnutrition, natural disasters and armed conflicts. In short, the work they do is so critical and we are proud to support it in any way we can."

Read more on Elsevier Connect.

Photos available on request. Contact Elisa Nelissen at [email protected] or +31 622 73 50 02.

About MSF
Médecins Sans Frontières (MSF) is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, natural disasters and exclusion from healthcare. MSF offers assistance to people based on need, irrespective of race, religion, gender or political affiliation. Our actions are guided by medical ethics and the principles of neutrality and impartiality. Thousands of health professionals, logistical and administrative staff - most of whom are hired locally - work on programmes in some 69 countries worldwide. http://www.msf.org

About Epicentre 

Created in 1986 by doctors from MSF, Epicentre is a nonprofit association, with a two-fold mission: research, contributing to the design and promotion of original operational medical projects in MSF intervention settings, or similar environments and training to support MSF teams in conducting operational response. Epicentre focuses on the most prevalent diseases: malaria, tuberculosis, HIV infection, children malnutrition, as well as diseases with epidemic potential: cholera, meningitis, measles, hemorrhagic fevers (yellow fever, Ebola, Marburg as well as Buruli ulcer, psychological care, sleeping sickness. Epicentre's research departments cover clinical and epidemiological research as well as training. Epicentre has a staff of around 40-people working in Europe (Paris, Geneva and Brussels) and 450 in Africa (Uganda and Niger). http://www.epicentre.msf.org

About the Elsevier Foundation 

The Elsevier Foundation is a corporate not-for-profit 501(c)(3), funded by Elsevier, a global provider of scientific, technical and medical information products and services. The Elsevier Foundation provides grants to knowledge centered institutions around the world, with a sustainability focus on innovations in health information, diversity in STM, research in developing countries and technology for development. Since its inception, the Foundation has awarded more than 100 grants worth over $6 million to non-profit organizations working in these fields. Through gift-matching, the Foundation also supports the efforts of Elsevier employees to play a positive role in their local and global communities. http://www.elsevierfoundation.org

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. http://www.elsevier.com

Media contact
Elisa Nelissen
Press Officer, Elsevier
+31 622 73 50 02
[email protected]

SOURCE Elsevier

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Elsevier appoints Brent Gordon President of Healthcare Education unit

Elsevier appoints Brent Gordon President of Healthcare Education unit

Elsevier, a global leader in information and analytics for science and healthcare, today announced the appointment of Brent Gordon as president of...

Elsevier launches PharmaPendium AI, designed to support faster and more reliable access to regulatory insights for drug development

Elsevier launches PharmaPendium AI, designed to support faster and more reliable access to regulatory insights for drug development

Elsevier, a global information and analytics company, today launches PharmaPendium AI, a generative AI assistant for regulatory intelligence in drug...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Not For Profit

Not For Profit

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.